Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Artelo Biosciences, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +5 vs. Q3 2021
- Shares held
- 1.90M
- −86.4K (−4.4%) vs. Q3 2021
- Total value
- $984.0K
- −$585.0K (−37.3%) vs. Q3 2021
- New holders
- 8
- 3 more added
- Sold out
- 3
- 5 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARTL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 10 | $132.0K |
| Q1 2026 | 11 | $829.9K |
| Q4 2025 | 10 | $120.6K |
| Q3 2025 | 9 | $151.7K |
| Q2 2025 | 9 | $220.1K |
| Q1 2025 | 8 | $75.8K |
| Q4 2024 | 6 | $36.6K |
| Q3 2024 | 5 | $25.6K |
| Q2 2024 | 6 | $35.7K |
| Q1 2024 | 7 | $37.2K |
| Q4 2023 | 7 | $34.3K |
| Q3 2023 | 8 | $76.4K |
| Q2 2023 | 6 | $78.4K |
| Q1 2023 | 7 | $110.8K |
| Q4 2022 | 8 | $337.9K |
| Q3 2022 | 9 | $464.0K |
| Q2 2022 | 15 | $442.8K |
| Q1 2022 | 18 | $659.0K |
| Q4 2021 | 22 | $984.0K |
| Q3 2021 | 17 | $1.57M |
| Q2 2021 | 20 | $3.29M |
| Q1 2021 | 15 | $2.17M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Artelo Biosciences, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 46 | $0 | 0.00% | −968−95.5% | Reduced |
| Wells Fargo & Company | 150 | $0 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 65 | $0 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 2 | $0 | 0.00% | +2 | New |
| Global Wealth Management Investment Advisory, Inc. | 475 | $0 | 0.00% | +475 | New |
| Creative Financial Designs Inc | 1,075 | $1.00K | 0.00% | +1,075 | New |
| Tower Research Capital LLC (TRC) | 5,461 | $3.00K | 0.00% | −4,441−44.8% | Reduced |
| State Street Corp | 10,400 | $5.00K | 0.00% | +10,400 | New |
| Millennium Management LLC | 11,977 | $6.00K | 0.00% | +11,977 | New |
| HighTower Advisors, LLC | 16,000 | $8.00K | 0.00% | −56,000−77.8% | Reduced |
| Two Sigma Advisers, LP | 16,000 | $8.00K | 0.00% | −19,600−55.1% | Reduced |
| Susquehanna International Group, LLP | 16,284 | $8.00K | 0.00% | +16,284 | New |
| Two Sigma Securities, LLC | 24,622 | $13.0K | 0.00% | +24,622 | New |
| Commonwealth Equity Services, LLC | 27,470 | $14.0K | 0.00% | +27,470 | New |
| Northern Trust Corp | 62,521 | $32.0K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 78,586 | $41.0K | 0.00% | +50,702+181.8% | Added |
| Bank of New York Mellon Corp | 86,603 | $45.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 108,800 | $56.0K | 0.00% | −173,808−61.5% | Reduced |
| Geode Capital Management, LLC | 162,750 | $84.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 180,282 | $94.0K | 0.01% | +137,270+319.1% | Added |
| Kepos Capital LP | 200,000 | $104.0K | 0.01% | 00.0% | Unchanged |
| Vanguard Group Inc | 890,923 | $462.0K | 0.00% | +23,027+2.7% | Added |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −122,895−100.0% | Sold out |
| LVM Capital Management Ltd | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −35−100.0% | Sold out |